Analytical Data
-
Gene name
PILRA
- Application
-
Alternative Names
Cell surface receptor FDF03; FDF03; Inhibitory receptor PILR-alpha; paired immunoglobulin-like receptor alpha; Paired immunoglobulin-like type 2 receptor alpha; PILRA; PILRA_HUMAN
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UKJ1
-
Expression Region
1-226 aa
-
AA Sequence
MGRPLLLPLLPLLLPPAFLQPSGSTGSGPSYLYGVTQPKHLSASMGGSVEIPFSFYYPWELATAPDVRISWRRGHFHGQSFYSTRPPSIHKDYVNRLFLNWTEGQKSGFLRISNLQKQDQSVYFCRVELDTRSSGRQQWQSIEGTKLSITQGQQRTKATTPAREPFQNTEEPYENIRNEGQNTDPKLNPKLHLTQSTSQPPSPQEPPERDPVLCLKGLTNGQPSQD
-
Molecular Weight
50.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PILRA (Paired Immunoglobulin-like Type 2 Receptor Alpha) is a member of the immunoglobulin superfamily and is primarily expressed in immune cells, particularly in myeloid lineage cells. This receptor plays a crucial role in regulating immune responses, particularly in the context of inflammation and autoimmune diseases. Research has indicated that PILRA can modulate the activation of various immune pathways, influencing the balance between pro-inflammatory and anti-inflammatory signals. Furthermore, dysregulation of PILRA expression has been linked to several pathological conditions, including cancer and infectious diseases, making it an attractive target for therapeutic interventions. The recombinant expression of PILRA protein has enabled researchers to study its functional properties, signaling mechanisms, and interactions with other immune receptors, facilitating the understanding of its role in immune regulation. Advances in protein engineering and purification methods have allowed for the production of high-quality PILRA recombinant proteins, which are essential for both in vitro and in vivo studies. Investigating PILRA's biological functions can provide insights into potential therapeutic strategies, including the development of modulators that could enhance immune responses in cancer therapies or dampen excessive inflammation in autoimmune disorders. Thus, the study of PILRA, through recombinant protein research, holds significant promise for improving our understanding and treatment of various immune-related conditions.
